STAT3 and neoplasm: The rationale supporting this approach is based on STAT3 signaling activity that drives resistance through apoptosis [114], and further evidence that STAT3 inhibition may reverse apoptosis-mediated therapy resistance while re-sensitizing tumor cells to therapeutic agents [216,217].